Bayer & Millennium: There's Good News and Bad News
Despite the way analysts greeted the $465 million target-production deal between Bayer and Millennium, the deal isn't good news for the industry. Millennium is the best dealmaker in the industry and Bayer one of the few remaining Big Pharmas with both the financial resources to afford and the obvious need for what Millennium sells. This deal isn't the start of a trend; it's just the opposite.
You may also be interested in...
The decision limits US FDA discretion in determining how to regulate products that seem to meet both drug and device standards.
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.
Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.